Digital therapeutics company Big Health announced it acquired Limbix, a maker of prescription digital therapeutics aimed at treating depression in teens and young adults.
Limbix is the creator of SparkRx, a PDTx that uses the principles of cognitive behavioral therapy to address depression in teens and young adults ages 13 to 22.
The self-guided CBT-based treatment was released in October 2021...
Limbix, maker of a prescription digital therapeutic aimed at treating depression in teens, scooped up $15 million in Series A2 funding.
The round was led by GSR Ventures, with participation from Digital Garage, Storm Ventures, Bixink, DN Capital, Korean Investment Partners, E& Investment, Gaingels, MVP, Operator Partners, Mana Ventures and Pacific Health Ventures.
Limbix announced its $9...
For digital therapeutics companies, the FDA has often been viewed as the gatekeeper to getting products to the patients. However, today the conversation around efficacy and research is branching beyond just what ticks the FDA boxes, into what kinds of studies are needed to meet the expectations of stakeholders and end users. This morning at DTx East, a group of panelist discussed the current...
Digital mental health company Limbix scored $9 million in Series A funding. The new round was led by GSR Ventures with participation from sequoia Capital, Storm Ventures, NexGen Venture Partners and BIXINK Therapeutics.
This comes roughly four months after the Palo Alto-based startup was selected as one of 27 digital health companies in MassChallenge HealthTech’s 2020 accelerator class.
WHAT IT...
This morning accelerator MassChallenge HealthTech named its class of 2020, which includes 27 startups from all over the world. This year’s list of companies includes everything from a VR-enabled digital therapeutic to care coordination products.
Startups that made this year’s cohort will have access to co-working office space and a tailored curriculum that connects startups to advisors,...
